FY2025 EPS Estimates for Kodiak Sciences Boosted by Analyst

Key Points

• Chardan Capital raised its FY2025 earnings per share estimate for Kodiak Sciences from ($4.37) to ($4.25), maintaining a "Neutral" rating and a $14.00 target price.
• Kodiak Sciences missed analysts' consensus estimates by reporting (1.03) EPS for its last quarter, which was lower than the expected ((1.01) EPS).
• Several analysts have upgraded their ratings on Kodiak Sciences recently, with the stock's average target price now at $13.20.

Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - Investment analysts at Chardan Capital upped their FY2025 earnings per share estimates for shares of Kodiak Sciences in a research report issued to clients and investors on Monday, October 6th. Chardan Capital analyst D. Gataulin now forecasts that the company will post earnings of ($4.25) per share for the year, up from their prior forecast of ($4.37). Chardan Capital currently has a "Neutral" rating and a $14.00 target price on the stock. The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.45) per share. Chardan Capital also issued estimates for Kodiak Sciences' FY2026 earnings at ($3.22) EPS.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($1.03) earnings per share for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.02).

Other equities analysts also recently issued research reports about the company. JPMorgan Chase & Co. upgraded Kodiak Sciences from an "underweight" rating to a "neutral" rating and set a $15.00 price objective on the stock in a research note on Thursday, August 14th. Wall Street Zen upgraded Kodiak Sciences from a "sell" rating to a "hold" rating in a research note on Friday, September 26th. Jefferies Financial Group assumed coverage on Kodiak Sciences in a research note on Monday, September 22nd. They issued a "buy" rating and a $15.00 price objective on the stock. Barclays upgraded Kodiak Sciences from an "underweight" rating to an "equal weight" rating and upped their price objective for the company from $7.00 to $17.00 in a research note on Thursday, September 25th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Kodiak Sciences in a research note on Wednesday. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $13.20.

Kodiak Sciences Stock Up 1.6%

Shares of NASDAQ KOD opened at $14.46 on Thursday. Kodiak Sciences has a twelve month low of $1.92 and a twelve month high of $19.39. The stock's 50 day moving average price is $10.64 and its 200-day moving average price is $6.24. The company has a market capitalization of $763.78 million, a PE ratio of -3.81 and a beta of 2.67.

Institutional Investors Weigh In On Kodiak Sciences

Several institutional investors have recently made changes to their positions in the stock. Headlands Technologies LLC lifted its position in shares of Kodiak Sciences by 256.4% during the second quarter. Headlands Technologies LLC now owns 8,083 shares of the company's stock worth $30,000 after acquiring an additional 5,815 shares in the last quarter. Bridgeway Capital Management LLC increased its holdings in shares of Kodiak Sciences by 8.2% in the second quarter. Bridgeway Capital Management LLC now owns 101,900 shares of the company's stock worth $380,000 after purchasing an additional 7,700 shares during the period. Adage Capital Partners GP L.L.C. increased its holdings in shares of Kodiak Sciences by 55.1% in the second quarter. Adage Capital Partners GP L.L.C. now owns 2,055,707 shares of the company's stock worth $7,668,000 after purchasing an additional 730,000 shares during the period. Ameriprise Financial Inc. increased its holdings in shares of Kodiak Sciences by 171.3% in the second quarter. Ameriprise Financial Inc. now owns 266,354 shares of the company's stock worth $994,000 after purchasing an additional 168,192 shares during the period. Finally, Nantahala Capital Management LLC increased its holdings in shares of Kodiak Sciences by 11.3% in the second quarter. Nantahala Capital Management LLC now owns 590,884 shares of the company's stock worth $2,204,000 after purchasing an additional 60,171 shares during the period. Hedge funds and other institutional investors own 89.06% of the company's stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.